• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Oculis Holding AG

    8/1/25 4:05:10 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OCS alert in real time by email
    6-K 1 d921948d6k.htm 6-K 6-K
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 6-K

     

     

    REPORT OF FOREIGN ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    OF THE SECURITIES EXCHANGE ACT OF 1934

    For the Month of July 2025

    (Commission File No. 001-41636)

     

     

    Oculis Holding AG

    (Translation of registrant’s name into English)

     

     

    Bahnhofstrasse 20

    CH-6300

    Zug, Switzerland

    (Address of registrant’s principal executive office)

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F ☒    Form 40-F ☐

     

     
     


    INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

    Amended Loan Facility

    On July 31, 2025, Oculis Holding AG (the “Registrant”) entered into an amended and restated agreement for its existing loan facility (the “Amended Loan Agreement”) with Kreos Capital VII (UK) Limited (the “Lender”), which are funds and accounts managed by BlackRock, Inc. No amount was drawn at the signing of the Amended Loan Agreement. The Amended Loan Agreement replaces the prior loan agreement between the Registrant and the Lender dated May 29, 2024, with an upsized structure to provide the EUR equivalent of up to CHF 75.0 million in borrowing capacity (which may be increased to up to CHF 100.0 million) (the “Loan”), comprising tranches 1, 2 and 3, in the amounts of the EUR equivalents of CHF 25.0 million each, as well as an additional loan of the EUR equivalent of up to CHF 25.0 million, which may be made available by the Lender to the Registrant if mutually agreed in writing by the Lender and the Registrant.

    Loan 1 will be available for drawdown from closing until November 15, 2026, which period may be shortened upon the occurrence of a development milestone. Loans 2 and 3 will be available for drawdown prior to November 15, 2026 and December 31, 2026, respectively, in each case subject to satisfaction of certain pre-specified conditions. The availability of any funds under a drawdown of Loans 1, Loan 2 or Loan 3 is conditional upon, together with other conditions, the Registrant having a debt-to-market cap ratio (where debt includes the amount of all amounts drawn down to date and the proposed drawdown) equal to or less than 15% at the time of each draw down.

    Borrowings under Loan 1, 2 and 3 will bear interest at a fixed rate (cash and PIK) of 9.7%, 9.6% and 9.5% per annum, respectively. The Loan will have an interest-only period of, in respect of Loans 1, 2 and 3, from the relevant drawdown date until December 31, 2027, March 31, 2028 and June 30, 2028, respectively. The interest-only periods for each of Loans 1 and 2 will be shortened to December 31, 2026 if certain conditions are not met. In the event the interest-only periods for Loans 1 and 2 are shortened, Loans 1 and 2 will mature on 30 June 2029. In the event the interest-only periods are not shortened, Loans 1, 2 and 3 will expire on 31 December 2029.

    The Registrant may prepay all, but not part, of the term loan amounts at any time other than, unless the Lender agrees otherwise, by notifying the Lender in advance. The Loan is subject to mandatory prepayment in the event of a change of control or specified asset dispositions or licenses, subject to certain exceptions and thresholds. There are additional fees (including prepayment premia) payable to the Lender in the event the loan is prepaid either mandatorily or voluntarily. The Lender received a restatement fee of approximately CHF 500,000 in connection with the Amended Loan Agreement. The Lender is eligible to receive an aggregate of approximately CHF 562,500 in additional transaction fees payable upon the Registrant’s eligibility to receive and actual receipt of future drawdowns. The Lender will be eligible to receive certain non-utilisation fees. On the date on which the Loan is prepaid or falls due for repayment in full, the Lender is eligible to receive an end of loan fee of, in relation to each of Loans 1, 2 and 3, 4.5% of the amount drawn down under the relevant loan. The Loan contains customary affirmative and negative covenants.

    As additional consideration for the Loan, Kreos Capital VII Aggregator SCSp, an affiliate of the Lender (the “Holder”), and the Registrant entered into an amended warrant (the “Amended Warrant”) to purchase up to 494,259 of the Registrant’s ordinary shares, subject to vesting, at a price per ordinary share equal to $12.17 with respect to 361,011 shares from the prior warrant agreement, and $18.64 with respect to the remaining 133,248 shares reflecting the upsized facility, subject to adjustment (the “Exercise Price”). The Amended Warrant amends the prior warrant issued to Holder on May 29, 2024. As of the signing date, the Amended Warrant is exercisable for 59,310 ordinary shares, of which 43,321 shares were previously granted. Following the drawdown of each of Loans 1, 2 and 3, the Amended Warrant will become exercisable for additional amounts of ordinary shares ratably based on the amounts of Loans 1, 2 and 3 that are drawn. Each tranche of the Amended Warrant will be exercisable for a period of up to seven years from the date of vesting and the Amended Warrant will terminate at the earliest of (i) December 31, 2033, (ii) such earlier date on which the Amended Warrant is no longer exercisable for any warrant shares in accordance with its terms and (iii) the acceptance by the Registrant’s shareholders of a third-party bona fide offer for all outstanding shares of the Registrant (subject to any prior exercise by the Holder, if applicable). The Amended Warrant also includes customary F-3 resale and piggyback registration rights and anti-dilution provisions.


    The Registrant intends to use the proceeds from the Amended Loan Agreement for general corporate purposes.

    The foregoing summaries of the Amended Loan Agreement and the Amended Warrant are not complete and are qualified in their entirety by reference to the full text of the Amended Loan Agreement and the Amended Warrant, respectively, copies of which the Registrant expects to file no later than with its Annual Report on Form 20-F for the fiscal year ending December 31, 2025.

    INCORPORATION BY REFERENCE

    This information contained in this Report on Form 6-K is hereby incorporated by reference into the Registrant’s Registration Statements on Form S-8 (File Nos. 333-271938 and 333-287806) and Form F-3 (File Nos. 333-281798, 333-278409 and 333-271063).


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

        OCULIS HOLDING AG
    Date: August 1, 2025     By:  

    /s/ Sylvia Cheung

         

    Sylvia Cheung

    Chief Financial Officer

    Get the next $OCS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OCS

    DatePrice TargetRatingAnalyst
    12/5/2023$30.00Buy
    Chardan Capital Markets
    10/5/2023$35.00Buy
    Stifel
    6/14/2023$22.00Buy
    BofA Securities
    6/12/2023$28.00Buy
    H.C. Wainwright
    6/8/2023$58.00Outperform
    Robert W. Baird
    5/10/2023$23.00Buy
    Pareto
    4/28/2023$27.00Outperform
    Wedbush
    More analyst ratings

    $OCS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference

    ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs, today announced that Oculis' management will be participating in the H.C Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025. Sylvia Cheung, Oculis' Chief Financial Officer, will be presenting a corporate update which will be made available for replay via webcast at 7:00am ET Snehal Shah, Oculis' President of R&D, will be participating in a live panel discussion from 11:00am to 12:00pm ET, on Pivotal-Stage Assets

    8/12/25 4:00:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

    ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs, today announced that Oculis' management will be participating in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025. Sylvia Cheung, Oculis' Chief Financial Officer, will be presenting a corporate update which will be made available for replay via webcast at 7:00am ET.Snehal Shah, Oculis' President of R&D, will be participating in a live panel discussion from 11:00am to 12:00pm ET, on Pivotal-Stage Ass

    8/12/25 4:00:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oculis Upsized Loan Facility to Access up to CHF 100 million

    ZUG, Switzerland, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis" or the "Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it has amended its loan facility (the "Amended Loan Agreement") with funds and accounts managed by BlackRock (the "Lender"). The Amended Loan Agreement replaces the prior loan agreement between Oculis and the Lender dated May 29, 2024, and the upsized structure will provide CHF 75.0 million in borrowing capacity (which may be increased to up to CHF 100.0 million) (the "Loan"). The Loan comprises tra

    8/1/25 4:00:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital Markets initiated coverage on Oculis Holding AG with a new price target

    Chardan Capital Markets initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $30.00

    12/5/23 8:03:01 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Oculis Holding AG with a new price target

    Stifel initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $35.00

    10/5/23 7:50:21 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities initiated coverage on Oculis Holding AG with a new price target

    BofA Securities initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $22.00

    6/14/23 8:10:40 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCS
    SEC Filings

    View All

    SEC Form 6-K filed by Oculis Holding AG

    6-K - Oculis Holding AG (0001953530) (Filer)

    8/1/25 4:05:10 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Oculis Holding AG

    S-8 - Oculis Holding AG (0001953530) (Filer)

    6/5/25 4:38:25 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Oculis Holding AG

    6-K - Oculis Holding AG (0001953530) (Filer)

    6/5/25 4:05:17 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCS
    Leadership Updates

    Live Leadership Updates

    View All

    Oculis Publishes Invitation to the Annual General Meeting

    ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT. The 2025 Annual General Meeting will be held in-person and broadcast. To join the broadcast, please use the following link. Information pertaining to the 2025 Annual General Meeting, including meeting materials, can be accessed on the Oculis website here. Oculis will host a virtual information session for all shareholders on May 19, 2025 from 4:00 to 5:00 p.m. CEST / 10:00 to 11:00 a.m. EDT, during

    5/9/25 4:05:00 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

    Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

    10/8/24 5:00:00 AM ET
    $ENTO
    $OCS
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer

    Mr. Char brings extensive experience in leading legal, compliance and corporate governance functions in successful biotech and medical device companiesThe appointment further expands Oculis' leadership team as the company advances its late-stage pipeline and prepares for commercial phase ZUG, Switzerland, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the appointment of Daniel S. Char to the role of Chief Legal Officer, leading Oculis' legal, compliance and corporate governance functions. Mr. Char brings over 35 years of success in global legal leade

    10/2/24 4:00:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCS
    Financials

    Live finance-specific insights

    View All

    Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops

    DIAMOND trial in Diabetic Macular Edema (DME) with topical OCS-01 met its stage 1 objective of validating the loading and maintenance dosing regimen designed to optimize OCS-01 efficacy potential with robust statistical significancePrimary efficacy endpoint of mean change in Best Corrected Visual Acuity (BCVA) versus baseline at Week 6 showed statistically significant increase in visual acuity in the OCS-01 arm compared to vehicle armStatistically significant secondary endpoints showed higher percentage of patients achieving ≥15-letter improvement in BCVA and better improvement in retinal thickness in the OCS-01 arm versus vehicle armOCS-01 was well-tolerated with no unexpected adverse event

    5/22/23 6:30:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones

    ZUG, Switzerland and BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announces that it will host a virtual conference call and webcast to present an overview of its late-stage pipeline and discuss expected near-term clinical milestones on Thursday, April 13 from 8:00am-9:00am ET / 13:00-14:00 BST / 14:00-15:00 CET. Oculis is focused on becoming a leading global ophthalmic biopharmaceutical company with product candidates to address areas of significant medical needs, including diabetic macular edema (DME), dry eye disease (DED), and neuro-retina indica

    4/4/23 7:00:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Oculis Holding AG

    SC 13G - Oculis Holding AG (0001953530) (Subject)

    12/9/24 9:43:55 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Oculis Holding AG

    SC 13G/A - Oculis Holding AG (0001953530) (Subject)

    11/7/24 4:15:49 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care